宜通世纪（SZ300310）斥资10亿元跨界并购过来的标的，如今走到了破产终结的结局，而宜通世纪仅获得83万元的破产财产分配。 2月2日晚间，宜通世纪发布公告称，其曾经的全资子公司深圳市倍泰健康测量分析技术有限公司（以下简称"倍泰健康"）破产程序终结。 这起曾被寄予厚望、旨在跨界智慧医疗的收购，最终演变为一场"噩梦"。从2018年倍泰健康"爆雷"开始，宜通世纪不仅要因其业绩崩盘计提巨额商誉减 值，还惹了一身的麻烦。 不过，虽然倍泰健康的破产程序在法律上终结，但这起天价并购案留下的"后遗症"尚未完全平息。2025年11月，宜通世纪透露，公司因股权转让合同纠纷 起诉倍泰健康原股东一案，被发回重审。 倍泰健康破产程序终结 公司仅获83万元分配款 宜通世纪最新公告显示，公司近日收到广东省深圳市中级人民法院出具的《民事裁定书》，其债务人倍泰健康被法院裁定终结破产程序。 公告显示，倍泰健康的破产清算申请于2023年11月13日被法院受理，倍泰健康于2026年1月26日被法院裁定宣告破产。 据倍泰健康的《破产财产分配方案》，宜通世纪作为债权人，可获得分配的破产财产金额约83万元。宜通世纪在公告中表示，该事项预计将对公司利润 ...

Core Viewpoint - The article highlights the serious issue of commercial bribery in the medical sector, emphasizing the need for stringent measures to combat it and protect public health and the integrity of the healthcare system [1][2][3]. Group 1: Cases of Bribery - The National Healthcare Security Administration (NHSA) reported a case involving a hospital director in Shaanxi who illegally accepted 2.72 million yuan in bribes, primarily from orthopedic consumables [1]. - This case is part of a broader trend, with the NHSA exposing multiple instances of bribery in the medical field, indicating a rampant issue that undermines fair competition and increases medical costs [1][2]. Group 2: Nature of Commercial Bribery - Commercial bribery in the medical field distorts prescription rights and interferes with normal medical practices, leading to increased costs for patients and the healthcare system [2]. - The bribery cases reveal a pattern where suppliers offer high rebates to secure contracts, which ultimately inflates product prices and burdens patients and insurance funds [2][3]. Group 3: Systemic Issues and Reforms - The article discusses the systemic issues that allow commercial bribery to persist, including complex interest chains and regulatory loopholes, particularly in high-value consumables and pharmaceuticals [2][3]. - The NHSA has been increasing efforts to combat commercial bribery through administrative and criminal measures, emphasizing the need for comprehensive reforms in the procurement system to reduce incentives for bribery [3][4]. Group 4: Recommendations for Action - To effectively eliminate commercial bribery, a multi-faceted approach is necessary, including strict penalties for both bribers and recipients, improved internal decision-making processes in medical institutions, and enhanced transparency in procurement [4][5]. - The article stresses the importance of enforcing the principle of "joint investigation of bribery and acceptance" and the "dual penalty system" for companies and individuals involved in bribery [4][6]. Group 5: Broader Implications - The prevalence of commercial bribery not only harms public finances but also jeopardizes public health and social equity, as each bribe can lead to unnecessary medical expenses and inappropriate treatment choices [6]. - The ongoing efforts to combat medical commercial bribery are crucial for purifying the industry and safeguarding the health and welfare of the public [6].

Summary of WanDong Medical Conference Call Company Overview - **Company**: WanDong Medical - **Parent Company**: Midea Group - **Industry**: High-end medical equipment, focusing on CT, MR, and DSA technologies Key Points and Arguments Strategic Shift and Market Positioning - Since joining Midea Group in 2021, WanDong Medical has shifted its strategic focus towards the high-end medical equipment market, particularly in CT, MR, and DSA sectors, aiming to transition from traditional low to mid-end markets to high-end clients [2][5] - The company is actively expanding its overseas market presence, aligning with the "Belt and Road" initiative, which supports its internationalization strategy [2][5] Response to Market Challenges - The centralized procurement policy has provided WanDong Medical with opportunities to enter mainstream public hospital markets, despite facing pressure on gross margins [2][5] - The company is overcoming challenges by offering high cost-performance products and a flexible product matrix, launching new products like the 64-slice 128-layer cardiac CT and high-end 3T MRI [2][5] Internationalization and Collaboration - Midea Group's acquisition of Reiko International aims to enhance international business, with both companies complementing each other in product positioning and market reach [2][7] - Future capital operations may be implemented to avoid competition between WanDong and Reiko, ensuring optimal resource utilization [2][7] Innovation and R&D Focus - WanDong Medical is increasing its R&D investments, particularly in high-end medical imaging equipment, establishing a technology reserve system to enhance future product competitiveness [3][11] - The company is developing innovative products, including a helium-free MRI, which is expected to lead the market trend towards more sustainable technologies [12][18] Financial Performance and Market Strategy - Despite short-term profit pressures due to increased R&D and marketing expenses, the company is focused on long-term growth and value creation for shareholders [4][13] - WanDong Medical anticipates significant market share growth in mid to low-end CT and MRI markets, aiming for a top-three position in its segments by 2025 [15] AI and Smart Technology Integration - The company is investing in AI technologies for smart scanning, imaging, and management, aiming to transform imaging devices into intelligent systems [16][17] - Current projects include the development of smart DR systems and integrated diagnostic solutions for specific conditions like adolescent scoliosis [16][17] Future Outlook - WanDong Medical expects to maintain a strong growth trajectory, with a focus on high-end and innovative products, while expanding its international market share to 40-45% of total revenue by 2026 [15][19] - The company is committed to enhancing its operational efficiency and cost structure to improve overall profitability [11][14] Additional Important Insights - The company is strategically positioning itself to adapt to the ongoing changes in the medical equipment market, particularly with the implementation of centralized procurement policies [9][11] - WanDong Medical's approach to product differentiation and innovation is crucial for maintaining competitiveness against established players in the industry [12][19]

融资方面，迈得医疗当日融资买入929.92万元。当前融资余额6966.36万元，占流通市值的2.56%，融资 余额超过近一年70%分位水平，处于较高位。 2月2日，迈得医疗涨0.61%，成交额9509.37万元。两融数据显示，当日迈得医疗获融资买入额929.92万 元，融资偿还891.83万元，融资净买入38.09万元。截至2月2日，迈得医疗融资融券余额合计6966.36万 元。 融券方面，迈得医疗2月2日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，迈得医疗十大流通股东中，华夏行业景气混合A（003567）位居 第四大流通股东，持股260.36万股，相比上期减少106.61万股。交银稳健配置混合（519690）位居第七 大流通股东，持股137.68万股，为新进股东。交银科技创新灵活配置混合A（519767）位居第九大流通 股东，持股110.96万股，为新进股东。华夏远见成长一年持有混合A（016250）退出十大流通股东之 列。 声明：市场有风险，投资需谨慎。 ...

Group 1 - The core viewpoint of the article highlights that the latest technology achievement transformation index report from Zhejiang Province shows that Hangzhou, Ningbo, and Jiaxing have ranked the top three in the province for 2024, with Jiaxing maintaining a significant lead over the fourth-ranked city [1] - Jiaxing has established a comprehensive mechanism for the entire process of technology achievement transformation, focusing on collaborative innovation between industry, academia, and research [1][2] - The city has recognized 22 municipal-level concept verification centers, with 6 included in the provincial construction list, facilitating the verification and incubation of numerous projects [3] Group 2 - The "4+X" measurement framework introduced in the latest index evaluation focuses on four core dimensions: innovation research and development, achievement output, achievement transaction, and transformation performance, along with several unique indicators [2] - Jiaxing has hosted 14 innovation and entrepreneurship competitions, attracting 301 projects and resulting in 58 projects landing in the city, demonstrating a robust ecosystem for technology transfer [3] - The city has initiated a "Technology Vice President" program, pairing experts with enterprises to enhance the alignment of technical needs and innovation resources [4][5] Group 3 - Jiaxing is advancing a pilot reform for the integrated development of education and technology talent, with over 30 reform tasks underway, including the construction of a "first-use, then-transfer" achievement pool [5][6] - The city has established a mechanism for the entire process of technology achievement cultivation, evaluation, and closed-loop service, contributing to the construction of a highland for technology achievement transformation in the Yangtze River Delta [7] - Jiaxing has focused on enhancing the quality and efficiency of scientific research platforms, promoting the establishment of joint laboratories and research centers with enterprises [7]

迈得医疗工业设备股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688310 证券简称：迈得医疗 公告编号：2026-008 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，现将公司回购股份进展情况公告如下： 2026年1月，本次公司通过集中竞价交易方式已累计回购公司股份1,297,052股，占公司总股本 166,219,690股的比例为0.7803%，回购成交的最高价为16.20元/股，最低价为15.69元/股，支付的资金总 额为人民币20,660,204.79元（不含印花税、交易佣金等交易费用）。 截至2026年1月31日，本次公司通过集中竞价交易方式已累计回购公司股份1,297,052股，占公司总股本 166,219,690股的比例为0.7803%，回购成交的最高价为16.20元/股，最低价为15.69元/股，支付的资金总 额为人民币 ...

来源：新浪证券-红岸工作室 2月2日，海泰新光跌1.01%，成交额1.17亿元，换手率2.04%，总市值56.22亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 资金分析 今日主力净流入-772.68万，占比0.07%，行业排名100/135，连续2日被主力资金减仓；所属行业主力净 流入-6.62亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-772.68万-837.92万-850.46万-1696.85万-747.98 ...

Group 1 - The core viewpoint of the news is that Wandong Medical is expected to report significant losses in 2025, transitioning from profit to loss due to various operational challenges [1][3]. Group 2 - As of January 30, 2026, Wandong Medical's stock closed at 15.94 yuan, with a trading volume of 59,200 shares and a total transaction amount of 94.49 million yuan [1]. - On January 30, the net inflow of main funds was 272,500 yuan, accounting for 0.29% of the total transaction amount, while retail investors saw a net outflow of 287,290 yuan, representing 3.04% of the total [1][3]. Group 3 - Wandong Medical forecasts a net profit loss of between 199.73 million yuan and 257.83 million yuan for the year 2025, with a non-recurring net profit loss expected to be between 213.23 million yuan and 271.33 million yuan [1][3]. - The company attributes the expected losses to participation in centralized procurement of medical devices, adjustments in pricing strategies affecting gross margins, and increased investments in research and development as well as expansion into overseas and high-end markets [1][3].

截至2026年1月30日收盘，迈得医疗(688310)报收于16.3元，上涨1.62%，换手率2.2%，成交量3.66万 手，成交额5921.43万元。 公司公告汇总 迈得医疗工业设备股份有限公司拟向控股子公司浙江迈得顺隐形眼镜有限公司提供总额不超过人民币1 亿元的财务资助，资助期限为自股东会审议通过之日起3年内，借款利率参照一年期LPR，利息按实际 借款占用天数计算。迈得顺可循环使用额度。公司实际控制人林军华、持股5%以上股东陈万顺为本次 资助提供连带责任保证。本次资助事项构成关联交易，不构成重大资产重组。董事会已提请股东会授权 管理层办理相关协议签署及款项支付等事宜。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日主力资金净流出114.8万元，占总成交额1.94%。 来自公司公告汇总：迈得医疗拟向控股子公司浙江迈得顺提供不超过1亿元财务资助，借款利率参 照一年期LPR。 当日关注点 交易信息汇总资金流向 1月30日主力资金净流出114.8万元，占总成交额1.94%；游资资金净流出279.94万元，占 ...

Core Insights - The introduction of domestic Boron Neutron Capture Therapy (BNCT) devices marks a significant advancement in cancer treatment, showcasing the potential for domestic scientific innovations to enhance healthcare accessibility and efficiency [1][2][3] - The medical industry is experiencing a transformation driven by technological breakthroughs, particularly in high-end cancer treatment equipment, which has historically been dominated by foreign brands [1][2] Group 1: Technological Advancements - The BNCT technology has led to the development of targeted boron drugs, achieving a tumor-to-normal tissue boron concentration ratio of 5.2:1, and has spurred the localization of key materials such as high-purity oxygen-free copper [2] - The multi-modal cross-scale biomedical imaging facility in Beijing has passed national acceptance, establishing a comprehensive imaging system from molecular to organ levels, and has attracted 29 major digital life projects [2] - The domestic tumor electric field treatment system has catalyzed the development of supporting industries, creating a complete industrial chain covering research, manufacturing, and clinical application [2] Group 2: Industry Impact - The integration of large scientific devices into clinical settings is reshaping the medical industry ecosystem and driving collaborative upgrades across the entire industry chain [2] - The ultimate goal of the medical industry is to ensure that high-quality medical resources are accessible to a broader population, addressing the global demand for effective treatments for difficult-to-treat tumors [2][3] - The shift from being a follower to a leader in high-end medical equipment signifies a new chapter in technological innovation that empowers public health [3]